EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of Epstein-Barr virus-associated peripheral T-cell lymphoma



Treatment of Epstein-Barr virus-associated peripheral T-cell lymphoma



British Journal of Dermatology 150(5): 1038-1040



A 48-year-old woman with a follicular, grade III, B-cell non-Hodgkin lymphoma developed clinical, immunopathological and histological features of paraneoplastic pemphigus. The skin symptoms flared after repeated cyclophosphamide infusions, and were preceded and accompanied by a progressive dyspnoea. Although the skin and oral mucosal disease went into remission with high-dose steroid and intravenous immunoglobulin therapy, the severe alveolitis led to death. Immunoblotting of human epidermal extracts showed that the patient's serum IgG reacted with the 210-kDa envoplakin, 190-kDa periplakin, as well as the recombinant protein of BP180 NC16a domain. IgG and IgA enzyme-linked immunosorbent assays for desmoglein 3 were positive, too. Indirect immunofluorescence studies on COS-7 cells transiently transfected with desmocollin 1-3 cDNAs showed that the patient's serum contained IgG and IgA antibodies to desmocollin 3 as well as IgG antibodies to desmocollin 2. Serum IgG and IgA strongly stained rat bronchial epithelium, corresponding to autoantibodies possibly involved in the pathomechanism of the severe lung disease. In this case, which was characterized by a mixed IgA/IgG antibody panel displaying known and unique antigenicity, the serious episodes of paraneoplastic pemphigus flared after cyclophosphamide treatment.

(PDF same-day service: $19.90)

Accession: 035980402

Download citation: RISBibTeXText

PMID: 15149529

DOI: 10.1111/j.1365-2133.2004.05945.x



Related references

Relationship between the amounts of epstein barr virus dna and epstein barr virus nuclear antigen per cell clonability and tumorigenicity in 2 epstein barr virus negative lymphoma lines and their epstein barr virus converted sublines. International Journal of Cancer 31(2): 163-170, 1983

Establishment of epstein barr virus nuclear antigen expressing cell lines by infection of epstein barr virus genome negative human lymphoma cells with different epstein barr virus strains. International Journal Of Cancer: 161-166, 1976

An epstein barr virus genome negative cell line established from an american burkitts lymphoma receptor characteristics epstein barr virus infectibility and permanent conversion into epstein barr virus positive sublines by in vitro infection. Intervirology 5(6): 319-334, 1975

Concomitant Epstein-Barr virus-negative large B-cell lymphoma (Richter syndrome) and Epstein-Barr virus- positive B-cell lymphoproliferation after treatment with fludarabine and cyclophosphamide in a patient with B-cell chronic lymphocytic leukemia. Archives of Pathology & Laboratory Medicine 130(8): 1227-1230, 2006

Production by epstein barr virus infection of an epstein barr nuclear antigen positive subline from an epstein barr nuclear antigen negative human lymphoma cell line without detectable epstein barr virus dna. International Journal of Cancer 16(1): 125-133, 1975

Epstein-Barr virus-associated composite lymphoma composed of peripheral T-cell lymphoma and an anaplastic variant of a diffuse large B-cell type of non-Hodgkin's lymphoma and strongly expressing p53 protein. International Journal of Hematology 79(3): 260-265, 2004

The frequency of B- and T-cell gene rearrangements and epstein-barr virus in T-cell lymphomas: a comparison between angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma, unspecified with and without associated B-cell proliferations. Journal of Molecular Diagnostics 8(4): 466-75; Quiz 527, 2006

Inducibility of the epstein barr virus cycle and surface marker properties of epstein barr virus negative lymphoma lines and their in vitro epstein barr virus converted sublines. International Journal of Cancer 18(5): 639-652, 1976

Epstein-Barr virus-associated lymphoproliferative disorder presenting with classical Hodgkin lymphoma and developing as peripheral T-cell lymphoma 9 years later: a case report of composite lymphoma. Pathology International 61(12): 752-755, 2012

Induction of an activated b lymphocyte associated surface moiety defined by the b 2 mono clonal antibody by epstein barr virus conversion of an epstein barr virus negative lymphoma line ramos differential effect of transforming b 95 8 and nontransforming p 3hr 1 epstein barr virus substrains. Journal of Immunology 130(4): 1985-1989, 1983

Composite primary cutaneous peripheral T-cell lymphoma and Epstein-Barr virus-positive large B-cell lymphoma. Leukemia & Lymphoma 52(10): 2027-2030, 2012

Primary cutaneous, composite, Epstein-Barr virus-associated, diffuse large B-cell lymphoma and peripheral T-cell lymphoma. American Journal of Dermatopathology 33(7): 719-725, 2012

Epstein-Barr virus-positive diffuse large B-cell lymphoma following peripheral T-cell lymphoma, not otherwise specified: report of a case. Zhonghua Bing Li Xue Za Zhi 39(6): 414-415, 2011